SAN DIEGO, Aug. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company’s President and CEO Theodore Schroeder will present the corporate overview at two upcoming investment conferences in New York City:
-- Wednesday, September 5, 2007 at 11:00am Eastern Time (8:00am Pacific Time) during the Roth 2007 New York Conference, and -- Thursday, September 6, 2007 at 3:30pm Eastern Time (12:30pm Pacific Time) during the BIOCentury Newsmakers Conference.
These presentations will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals’ website at http://www.cadencepharm.com in the Investor Relations section. Replays of the webcasts will be available approximately one hour following the live webcasts and will be archived for 30 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, including intravenous acetaminophen (IV acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence’s pipeline, visit http://www.cadencepharm.com.
Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.
Contacts: William R. LaRue Anna Gralinska SVP & Chief Financial Officer Director, Investor Relations Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc. 858-436-1400 858-436-1452
Cadence Pharmaceuticals, Inc.
CONTACT: William R. LaRue, SVP & Chief Financial Officer, +1-858-436-1400,or Anna Gralinska, Director, Investor Relations, +1-858-436-1452, both ofCadence Pharmaceuticals, Inc.
Web site: http://www.cadencepharm.com/
